Helix BioPharma Income Statement

Financials in millions CAD. Fiscal year is August - July.

Millions CAD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Selling, General & Admin	1.68	1.84	3.26	1.05	1.5	3.25
Research & Development	1.58	3.56	5.98	5.28	4.54	5.88
Other Operating Expenses	-0.08	-0.14	-0.05	-	-	-
Total Operating Expenses	3.18	5.26	9.19	6.33	6.04	9.13
Operating Income	-3.18	-5.26	-9.19	-6.33	-6.04	-9.13
Interest Income	0	0.02	0.03	0.05	0	-
Interest Expense	-0.03	-0.01	-0.01	-0.01	-0.02	-0.02
Other Non-Operating Income (Expense)	0.04	0.32	-	0	-0.51	-0.43
Total Non-Operating Income (Expense)	0.01	0.33	0.02	0.04	-0.52	-0.44
Pretax Income	-3.17	-4.93	-9.17	-6.29	-6.57	-9.57
Net Income	-3.17	-4.93	-9.17	-6.29	-6.57	-9.57
Earnings From Discontinued Operations	-	-	-	-	-	1.54
Net Income to Common	-3.17	-4.93	-9.17	-6.29	-6.57	-8.04
Shares Outstanding (Basic)	79	55	44	39	33	27
Shares Outstanding (Diluted)	79	55	44	39	33	27
Shares Change (YoY)	71.44%	25.53%	11.03%	19.76%	22.51%	4.90%
EPS (Basic)	-0.04	-0.09	-0.21	-0.16	-0.20	-0.30
EPS (Diluted)	-0.04	-0.09	-0.21	-0.16	-0.20	-0.30
Free Cash Flow	-3.21	-3.83	-5.23	-5.54	-6.51	-9.3
Free Cash Flow Per Share	-0.04	-0.07	-0.12	-0.14	-0.20	-0.35
EBITDA	-3.18	-5.25	-9.18	-6.31	-6.03	-8.93
EBIT	-3.18	-5.26	-9.19	-6.33	-6.04	-9.13